Twelve-Month Follow-up of the Immune Response After COVID-19 Vaccination in Patients with Genitourinary Cancers: A Prospective Cohort Analysis.
Luis MezaZeynep ZenginSabrina SalgiaJasnoor MalhotraEwa KarczewskaTanya Barauskas DorffAbhishek TripathiJennifer ElyErin KelleyHeather MeadJo Ann HsuNazli DizmanNicholas SalgiaNeal ChawlaAlex Chehrazi-RaffleRamya MuddasaniAmeish GovindarajanAdam RockSandy LiuRavi SalgiaJeffrey TrentJohn AltinSumanta K PalPublished in: The oncologist (2023)
Only a minority of patients with genitourinary cancers did not ultimately achieve satisfactory seroconversion after receiving commercial COVID-19 vaccination. Cancer type or treatment rendered did not appear to affect the immune response mounted after vaccination.